A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT ID: NCT06988488
Last Updated: 2026-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
62 participants
INTERVENTIONAL
2025-10-07
2027-06-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06163898
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
NCT06645678
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
NCT05981209
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
NCT07032714
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01478048
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1
Elranatamab
Specified dose on specified days
Mezigdomide
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Phase 2
Elranatamab
Specified dose on specified days
Mezigdomide
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Elranatamab
Specified dose on specified days
Mezigdomide
Specified dose on specified days
Dexamethasone
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable MM by local laboratory.
* Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
* Adherence to contraception requirements.
Exclusion Criteria
* Prior treatment with T cell engaging or T cell engager (TCE).
* Prior treatment with B cell-maturation antigen (BCMA)-targeting therapy, with the exception of participants who have received autologous BCMA-targeted CART-cell therapy\> 6 months from the start of study therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Yale New Haven Hospital-Smilow Cancer Center
New Haven, Connecticut, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Local Institution - 0026
Vancouver, British Columbia, Canada
Local Institution - 0027
Halifax, Nova Scotia, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Local Institution - 0030
Suzhou, Jiangsu, China
Local Institution - 0031
Shanghai, Shanghai Municipality, China
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, , Germany
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, , Germany
Universitaetsklinikum Heidelberg
Heidelberg, , Germany
Evangelismos General Hospital of Athens
Athens, Attikí, Greece
Alexandra General Hospital of Athens
Athens, Attikí, Greece
St. Olavs Hospital
Trondheim, Sør-Trøndelag, Norway
Sykehusapoteket Ull
Oslo, , Norway
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
Salamanca, , Spain
University College London Hospital
London, England, United Kingdom
Royal Marsden Hospital (Sutton)
London, Sutton, United Kingdom
The Christie NHS Foundation Trust
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role: CONTACT
First line of the email MUST contain the NCT# and Site #.
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Luciano Costa, Site 0001
Role: primary
Noffar Bar, Site 0029
Role: primary
David Siegel, Site 0028
Role: primary
Jing Christine Ye, Site 0005
Role: primary
Nizar Bahlis, Site 0032
Role: primary
Site 0026
Role: primary
Site 0027
Role: primary
Guido Lancman, Site 0024
Role: primary
Site 0030
Role: primary
Site 0031
Role: primary
Raphael Teipel, Site 0015
Role: primary
Katja Weisel, Site 0013
Role: primary
Marc-Steffen Raab, Site 0014
Role: primary
Sosana Delimpasi, Site 0011
Role: primary
MELETIOS DIMOPOULOS, Site 0012
Role: primary
Tobias Slordahl, Site 0017
Role: primary
Fredrik Hellem Schjesvold, Site 0019
Role: primary
Enrique Ocio, Site 0021
Role: primary
Maria Victoria Mateos Manteca, Site 0022
Role: primary
Selina Chavda, Site 0016
Role: primary
Charlotte Pawlyn, Site 0018
Role: primary
Emma Searle, Site 0020
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-522090-11
Identifier Type: OTHER
Identifier Source: secondary_id
U1111-1317-4901
Identifier Type: OTHER
Identifier Source: secondary_id
CA057-1040
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.